Updating on primary fallopian tube carcinoma

References

• Baekelandt M, Jorunn Nesbakken A, Kristensen GB, Trope CG, Abeler VM. Carcinoma of the fallopian tube. Cancer. 2000; 89: 2076–84
   PubMed Web of Science ®Google Scholar
• Schink J, Lurain J. Rare gynecological malignancies. Curr Opin Obstet Gynecol. 1991; 3: 78–90
   PubMed Web of Science ®Google Scholar
• Pettersson F. Staging rules for gestational trophoblastic tumors and fallopian tube cancer. Acta Obstet Gynecol Scand. 1992; 71: 224–5
   PubMed Web of Science ®Google Scholar
• Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. 1999; 72: 367–79
   PubMed Web of Science ®Google Scholar
• Riska A, Alfthan H, Finne P, Jalkanen J, Sorvari T, Stenman UH, et al. Preoperative serum hCGbeta as a prognostic marker in primary fallopian tube carcinoma. Tumor Biol. 2006; 27: 43–9
   PubMed Web of Science ®Google Scholar
• Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol. 1989; 35: 236–9
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER program. 12 geographic areas for 1995–1999. Bethesda, MD: National Cancer Institute, Cancer Statistic Branch; 2001.
   Google Scholar
• Clayton NL, Jaaback KS, Hirschowitz L. Primary fallopian tube carcinoma – the experience of a UK cancer centre and a review of the literature. J Obstet Gynaecol. 2005; 25: 694–702
   PubMedGoogle Scholar
• Pfeiffer P, Mogensen H, Amtrup F, Honore E. Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish cancer registry in a five-year period. Acta Oncol. 1989; 28: 7–11
   PubMed Web of Science ®Google Scholar
• Hellström AC, Silfverswärd C, Nilsson B, Pettersson F. Carcinoma of the fallopian tube. A clinical and histopathologic review. The Radiumhemmet series. Int J Gynecol Cancer. 1994; 4: 395–400
   PubMed Web of Science ®Google Scholar
• Riska A, Leminen A, Pukkala E. Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953–97. Int J Cancer. 2003; 104: 643–5
   PubMed Web of Science ®Google Scholar
• Vasama-Neuvonen K, Pukkala E, Paakkulainen H, Mutanen P, Weiderpass E, Boffetta P, et al. Ovarian cancer and occupational exposures in Finland. Am J Ind Med. 1999; 36: 83–9
   PubMed Web of Science ®Google Scholar
• Demopoulos RI, Aronov R, Mesia A. Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study. Int J Gynecol Pathol. 2001; 20: 128–32
   PubMed Web of Science ®Google Scholar
• Gungor T, Keskin HL, Zergeroglu S, Keskin EA, Yalcin H, Aydogdu T, et al. Tuberculous salpingitis in two of five primary fallopian tube carcinomas. J Obstet Gynaecol. 2003; 23: 193–5
   PubMedGoogle Scholar
• Riska A, Finne P, Alfthan H, Anttila T, Jalkanen J, Sorvari T, et al. Past chlamydial infection is not associated with primary fallopian tube carcinoma. Eur J Cancer. 2006; 42: 1835–8
   PubMed Web of Science ®Google Scholar
• Riska A, Finne P, Koskela P, Alfthan H, Jalkanen J, Lehtinen M, et al. Human papillomavirus infection and primary fallopian tube carcinoma: a seroepidemiological study. BJOG. 2007; 114: 425–9
   PubMed Web of Science ®Google Scholar
• Heselmeyer K, Hellström AC, Blegen H, Schrock E, Silfverward C, Shah K, et al. Primary carcinoma of fallopian tube: comparative genomic hybridization reveals high genetic instability and a specific, recurring pattern of chromosomal aberrations. Int J Gynecol Pathol. 1998; 17: 245–54
   PubMed Web of Science ®Google Scholar
• Riska A, Sund R, Pukkala E, Gissler M, Leminen A. Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975–2004. Int J Cancer. 2007; 120: 1351–4
   PubMed Web of Science ®Google Scholar
• Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Incidence of ovarian cancer of grand multigparous women – a population-based study in Finland. Gynecol Oncol. 2006; 1: 207–11
   Web of Science ®Google Scholar
• Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer. 2002; 6: 912–5
   Web of Science ®Google Scholar
• Hinkula M, Pukkala E, Kyyronen P, Kauppila A. Grand multiparity and the risk of breast cancer: population-based study in Finland. Cancer Causes Control. 2001; 12: 491–500
   PubMed Web of Science ®Google Scholar
• Lambe M, Wuu J, Weiderpass E, Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control. 1999; 10: 43–9
   PubMed Web of Science ®Google Scholar
• Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol. 2001; 80: 341–5
   PubMed Web of Science ®Google Scholar
• Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004; 23: 35–40
   PubMed Web of Science ®Google Scholar
• Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?. Obstet Gynecol. 2005; 106: 1327–34
   PubMed Web of Science ®Google Scholar
• Rosen AC, Ausch C, Klein M, Graf AH, Metzenbauer M, Philipp K, et al. p53 expression in fallopian tube carcinomas. Cancer Lett. 2000; 156: 1–7
   PubMed Web of Science ®Google Scholar
• Vousden KH, Lane DP. P53 in health and disease. Nat Rev Mol Cell Biol. 2007; 8: 275–83
   PubMed Web of Science ®Google Scholar
• Zheng W, Sung CJ, Cao P, Zhang ZF, Cai R, Godwin TA, et al. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. Gynecol Oncol. 1997; 64: 38–48
   PubMed Web of Science ®Google Scholar
• Chung TK, Cheung TH, To KF, Wong YF. Overexpression of p53 and HER-2/neu and c-myc in primary fallopian tube carcinoma. Gynecol Obstet Invest. 2000; 49: 47–51
   PubMed Web of Science ®Google Scholar
• Ajithkumar TV, Minimole AL, John MM, Ashokkumar OS. Primary fallopian tube carcinoma. Obstet Gynecol Surv. 2005; 60: 247–52
   PubMed Web of Science ®Google Scholar
• Tavassoli FA, Devilee P World Health Organization Classification of Tumors. Pathology and genetics of tumors of the breast and female genital organs. IARC Press: Lyon; 2003.
   Google Scholar
• Kol S, Gal D, Friedman M, Paldi E. Preoperative diagnosis of fallopian tube carcinoma by transvaginal sonography and CA-125. Gynecol Oncol. 1990; 37: 129–31
   PubMed Web of Science ®Google Scholar
• Hosokawa C, Tsubakimoto M, Inoue Y, Nakamura T. Bilateral primary fallopian tube carcinoma: findings on sequential MRI. AJR Am J Roentgenol. 2006; 186: 1046–50
   PubMed Web of Science ®Google Scholar
• Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Jr, Knapp RC, Bast RC, Jr. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984; 148: 1057–8
   PubMed Web of Science ®Google Scholar
• Lootsma-Miklosova E, Aalders JG, Willemse PH, de Bruijn HW. Levels of CA 125 in patients with recurrent carcinoma of the fallopian tube: two case histories. Eur J Obstet Gynecol Reprod Biol. 1987; 24: 231–5
   PubMed Web of Science ®Google Scholar
• Rosen AC, Klein M, Rosen HR, Graf AH, Lahousen M, Reiner A, et al. Preoperative and postoperative CA-125 serum levels in primary fallopian tube carcinoma. Arch Gynecol Obstet. 1994; 255: 65–8
   PubMed Web of Science ®Google Scholar
• Hefler LA, Rosen AC, Graf AH, Lahousen M, Klein M, Leodolter S, et al. The clinical value of serum concentrations of cancer antigen 125 in patients with primary fallopian tube carcinoma: a multicenter study. Cancer. 2000; 89: 1555–60
   PubMed Web of Science ®Google Scholar
• Braunstein GD, Vaitukaitis JL, Ross GT. The in vivo behavior of human chorionic gonadotropin after dissociation into subunits. Endocrinology. 1972; 91: 1030–6
   PubMed Web of Science ®Google Scholar
• Vartiainen J, Lehtovirta P, Finne P, Stenman UH, Alfthan H. Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. Int J Cancer. 2001; 95: 313–6
   PubMed Web of Science ®Google Scholar
• Baekelandt M, Kockx M, Wesling F, Gerris J. Primary adenocarcinomas of fallopian tube. Review of the literature. Int J Gynecol Cancer. 1993; 3: 65–71
   PubMed Web of Science ®Google Scholar
• Nordin AJ. Primary carcinoma of the fallopian tube: a 20-year literature review. Obstet Gynecol Surv. 1994; 49: 349–61
   PubMedGoogle Scholar
• Obermair A, Taylor KH, Janda M, Nicklin JL, Crandon AJ, Perrin L. Primary fallopian tube carcinoma: the Queensland experience. Int J Gynecol Cancer. 2001; 11: 69–72
   PubMed Web of Science ®Google Scholar
• Benoit MF, Hannigan EV. A 10-year review of primary fallopian tube cancer at a community hospital: a high association of synchronous and metachronous cancers. Int J Gynecol Cancer. 2006; 6: 29–35
   Web of Science ®Google Scholar
• Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist. 2006; 11: 902–12
   PubMed Web of Science ®Google Scholar
• Plentl A, Friedman E. Lymphatics of the fallopian tube. Lymphatic system of the female genitalia, A Plentl, E Friedman. WB Saunders, Philadelphia, PA 1971; 153–67
   Google Scholar
• Tamimi H, Figge D. Adenocarcinoma of the uterine tube:potential for lymph node metastases. Am J Obstet Gynecol. 1981; 141: 132–7
   PubMed Web of Science ®Google Scholar
• di Re E, Grosso G, Raspagliesi F, Baiocchi G. Fallopian tube cancer: incidence and role of lymphatic spread. Gynecol Oncol. 1996; 62: 199–202
   PubMed Web of Science ®Google Scholar
• Sedlis A. Carcinoma of the fallopian tube. Surg Clin North Am. 1978; 58: 121–9
   PubMed Web of Science ®Google Scholar
• Gadducci A. Current management of fallopian tube carcinoma. Curr Opin Obstet Gynecol. 2002; 14: 27–32
   PubMed Web of Science ®Google Scholar
• Tresukosol D, Kudelka AP, Edwards CL, Fromm GL, Mante R, Kavanagh JJ. Primary fallopian tube adenocarcinoma: clinical complete response after salvage treatment with high-dose paclitaxel. Gynecol Oncol. 1995; 58: 258–61
   PubMed Web of Science ®Google Scholar
• Gemignani ML, Hensley ML, Cohen R, Venkatraman E, Saigo PE, Barakat RR. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol. 2001; 80: 16–20
   PubMed Web of Science ®Google Scholar
• Kosary C, Trimble EL. Treatment and survival for women with fallopian tube carcinoma: a population-based study. Gynecol Oncol. 2002; 86: 190–1
   PubMed Web of Science ®Google Scholar
• Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes E, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. J Clin Oncol. 2000; 18: 2733–9
   PubMed Web of Science ®Google Scholar
• Riska A, Pukkala E, Scelo G, Mellemkjaer L, Hemminki K, Weiderpass Vainio E, et al. Second primary malignancies in females with primary fallopian tube carcinoma. Int J Cancer. 2007; 120: 2047–61
   PubMed Web of Science ®Google Scholar
• Iles RK, Persad R, Trivedi M, Sharma KB, Dickinson A, Smith P, et al. Urinary concentration of human chorionic gonadotrophin and its fragments as a prognostic marker in bladder cancer. Br J Urol. 1996; 77: 61–9
   PubMedGoogle Scholar
• Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Annu Rev Biochem. 1981; 50: 465–95
   PubMed Web of Science ®Google Scholar
• Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer. 2000; 82: 1553–6
   PubMed Web of Science ®Google Scholar
• Iles RK. Ectopic hCGbeta expression by epithelial cancer: malignant behaviour, metastasis and inhibition of tumor cell apoptosis. Mol Cell Endocrinol. 2007; 260–72: 264–70
   Web of Science ®Google Scholar
• Delves PJ, Iles RK, Roitt IM, Lund T. Designing a new generation of anti-hCG vaccines for cancer therapy. Mol Cell Endocrinol. 2006; 260–2: 276–84
   Web of Science ®Google Scholar